Dr. David (Dedi) Meiri
Assistant Professor, Heads the "Laboratory of Cancer Biology and Cannabinoid Research", Technion, Israel Institute of Technology
Ph.D, Assistant Professor Genetics, Cell Biology, Molecular Biology researcher
Dr. Meiri’s scientific background is highly diverse; He holds a M.Sc. in Biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on the role of the GEF-H1 protein in tumor invasion and metastasis. During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and succeeded within a very short timeframe, to receive worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs) and small GTPases. Upon completion of his post-doctoral fellowship, Dr Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.
Presently, his lab is investigates the therapeutic potential of phytocannabinoids, the unique active compounds of Cannabis. On-top on few other studies conducting in the lab, the main focus is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects phytocannabinoids exert, on a spectrum of tumor cells.
Additional to ‘basic science’, Dr. Meiri collaborates with cannabis growers, clinicians and major manufacturers and distributors of medical cannabis in the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in seven clinical trials covering diverse aspects of cannabis treatment, such as: colon disease, pain prevention, cancer treatment and epilepsy.